267 related articles for article (PubMed ID: 34332789)
21. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
22. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
23. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Tivey A; Shotton R; Eyre TA; Lewis D; Stanton L; Allchin R; Walter H; Miall F; Zhao R; Santarsieri A; McCulloch R; Bishton M; Beech A; Willimott V; Fowler N; Bedford C; Goddard J; Protheroe S; Everden A; Tucker D; Wright J; Dukka V; Reeve M; Paneesha S; Prahladan M; Hodson A; Qureshi I; Koppana M; Owen M; Ediriwickrema K; Marr H; Wilson J; Lambert J; Wrench D; Burney C; Knott C; Talbot G; Gibb A; Lord A; Jackson B; Stern S; Sutton T; Webb A; Wilson M; Thomas N; Norman J; Davies E; Lowry L; Maddox J; Phillips N; Crosbie N; Flont M; Nga E; Virchis A; Camacho RG; Swe W; Pillai A; Rees C; Bailey J; Jones S; Smith S; Sharpley F; Hildyard C; Mohamedbhai S; Nicholson T; Moule S; Chaturvedi A; Linton K
Blood Adv; 2024 Mar; 8(5):1209-1219. PubMed ID: 38127279
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS
Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928
[TBL] [Abstract][Full Text] [Related]
26. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A; Wu EQ; Patwardhan P
J Health Econ Outcomes Res; 2022; 9(2):19-29. PubMed ID: 35979528
[No Abstract] [Full Text] [Related]
27. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Cavazos N; Liu B; Yang S; Clow F; Goldberg JD; Beaupre D; Vermeulen J; Wildgust M; Wang M
Br J Haematol; 2017 Nov; 179(3):430-438. PubMed ID: 28832957
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
[TBL] [Abstract][Full Text] [Related]
29. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
[TBL] [Abstract][Full Text] [Related]
30. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
[TBL] [Abstract][Full Text] [Related]
31. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
Maruyama D; Omi A; Nomura F; Touma T; Noguchi Y; Takebe K; Izutsu K
Int J Hematol; 2024 Feb; 119(2):146-155. PubMed ID: 38195971
[TBL] [Abstract][Full Text] [Related]
34. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
Steinmetz TH; Singh M; Lebioda A; Fink L; Schoehl M; Rieth A; Gonzalez-McQuire S; Engelhardt M
J Med Econ; 2021; 24(1):114-122. PubMed ID: 33390079
[TBL] [Abstract][Full Text] [Related]
35. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
36. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.
Goyal RK; Nagar SP; Kabadi SM; Kaye JA; Seal B; Mato AR
Leuk Lymphoma; 2019 Apr; 60(4):955-963. PubMed ID: 30277099
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
Szabo SM; Hirji I; Johnston KM; Juarez-Garcia A; Connors JM
PLoS One; 2017; 12(10):e0180261. PubMed ID: 28991893
[TBL] [Abstract][Full Text] [Related]
39. Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
Irwin D; Wilson K; Thompson S; Choudhry A
Curr Med Res Opin; 2021 Apr; 37(4):623-628. PubMed ID: 33563073
[TBL] [Abstract][Full Text] [Related]
40. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
Cai B; Said Q; Li X; Li FY; Arcona S
J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
